Showing results (101-110 of 408) with videos related to
Sort By:
Pageof 41
Virology|June 23, 2009
Characterization of a trimeric MPER containing HIV-1 gp41 antigenAndreas Hinz, Guy Schoehn, Heribert Quendler, et al.Nature Communications|June 6, 2017
Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeysBrandon F Keele, Wenjun Li, Erica N Borducchi, et al.Science (New York, N.Y.)|June 27, 2015
HIV-1 ENVELOPE. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoproteinJia Chen, James M Kovacs, Hanqin Peng, et al.The Journal of Experimental Medicine|August 4, 2010
Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitnessJohn Pietzsch, Johannes F Scheid, Hugo Mouquet, et al.Journal of Virology|December 13, 2003
Subsets of memory cytotoxic T lymphocytes elicited by vaccination influence the efficiency of secondary expansion in vivoMichael S Seaman, Fred W Peyerl, Shawn S Jackson, et al.Virology|June 30, 2007
Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogensMichael S Seaman, Daniel F Leblanc, Lauren E Grandpre, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|October 30, 2016
Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific AntibodiesRuijiang Song, Craig Pace, Michael S Seaman, et al.Vaccines|November 25, 2023
Circularized Nanodiscs for Multivalent Mosaic Display of SARS-CoV-2 Spike Protein AntigensMoustafa T Mabrouk, Asmaa A Zidan, Nihal Aly, et al.Plos One|April 28, 2010
Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypesCatarina E Hioe, Terri Wrin, Michael S Seaman, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|May 24, 2014
Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36Ming Sun, Craig S Pace, Xin Yao, et al.Pageof 41